Form 4: COMPASS Pathways Director Daphne Karydas Granted 26,000 Share Options

Daphne Karydas, a Director at COMPASS Pathways plc, acquired 26,000 share options with an exercise price of $4.52, vesting by June 2026.

Summary

• Daphne Karydas, a Director of COMPASS Pathways plc (CMPS), acquired 26,000 share options on June 12, 2025.
• Each option has an exercise price of $4.52.
• The options will vest in full upon the earlier of June 12, 2026 (the first anniversary of the grant date) or the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026.
• The expiration date for these share options is June 11, 2035.
• Following this transaction, Ms. Karydas beneficially owns 26,000 derivative securities (share options).
• Each share option represents the right to buy one Ordinary Share, which may be represented by an American Depositary Share (ADS).

Sentiment

Score: 7

Explanation: The grant of options to a director is generally a positive signal as it aligns management's interests with long-term shareholder value. It's a routine compensation event, not a direct operational or financial performance indicator, hence not extremely high, but positive.

Positives

• The acquisition of share options by a director aligns their interests with those of shareholders, as the director's potential compensation is tied to the company's stock performance.
• The long expiration date of June 11, 2035, provides a significant window for the options to become in-the-money, suggesting a long-term perspective on the company's value creation.

Risks

• The value of the granted options is contingent on the future stock price of COMPASS Pathways plc; if the stock price does not exceed the exercise price of $4.52, the options may expire worthless.

Future Outlook

This filing does not provide a general future outlook for the company. However, the long-term nature of the option grant, expiring in 2035, implies a long-term perspective on the company's potential growth from the perspective of its compensation structure.

Industry Context

The grant of share options is a common practice in the biotechnology and pharmaceutical industry, particularly for companies like COMPASS Pathways plc, which are often in development stages. Equity-based compensation is widely used to attract and retain talent, aligning their interests with long-term shareholder value creation. This transaction represents a standard compensation mechanism.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across various industries, including biotechnology. The specific terms (exercise price, vesting schedule, expiration) are typically benchmarked against peer companies to ensure competitive compensation.
• Without specific peer compensation data, a direct comparison of the 'results' (i.e., the grant itself) is not possible, but the mechanism is standard. For example, similar equity grants are common at companies like MindMed (MNMD) or Atai Life Sciences (ATAI) in the psychedelic-assisted therapy space, or broader biotech firms, where long-term incentives are crucial for attracting and retaining key personnel.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially motivating long-term value creation.

Next Steps

• The options will vest on the earlier of June 12, 2026, or the date of COMPASS Pathways plc's Annual General Meeting of Shareholders in 2026.
• Daphne Karydas may choose to exercise these options at any point after vesting and before the expiration date of June 11, 2035, assuming the stock price is above the exercise price.

Key Dates

Keywords

COMPASS Pathways plc, CMPS, Form 4, Insider Transaction, Share Options, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership